Literature DB >> 12105105

Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis.

Kunio Yui1, Shigenori Ikemoto, Kimihiko Goto.   

Abstract

The relation between increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic changes, and susceptibility to subsequent spontaneous recurrences of methamphetamine (MAP) psychosis (flashbacks) was examined. Plasma monoamine metabolite levels were assayed in 19 flashbackers, of whom 10 experienced a single flashback and 9 exhibited subsequent flashbacks, 18 nonflashbackers with a history of MAP psychosis, 9 subjects with persistent MAP psychosis, and 22 MAP user and 10 nonuser controls. All flashbackers had undergone frightening stressful experiences during previous MAP use. They exhibited flashbacks in response to mild psychosocial stressors. There was no significant difference in the number of stressful experiences and having mild psychosocial stressors between the two flashbacker subgroups. Plasma norepinephrine (NE) levels increased with a small increase in plasma levels of 3-methoxytyramine (3-MT), an index of dopamine release, during flashbacks in the 19 flashbackers. Of the 19 flashbackers, the 9 with subsequent episodes had markedly increased NE levels and slightly increased 3-MT levels during flashbacks, while the 10 with a single episode displayed small increases in NE and 3-MT levels during flashbacks. The 9 flashbackers with subsequent episodes had a longer duration of imprisonment than the 10 flashbackers with a single episode. Thus, robust noradrenergic hyperactivity with slightly increased DA release in response to mild stress may predict subsequent flashbacks. Long-term exposure to distressing situations appears to contribute to susceptibility to subsequent flashbacks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105105     DOI: 10.1111/j.1749-6632.2002.tb04171.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

Review 1.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

Review 2.  Potential adverse effects of amphetamine treatment on brain and behavior: a review.

Authors:  S M Berman; R Kuczenski; J T McCracken; E D London
Journal:  Mol Psychiatry       Date:  2008-08-12       Impact factor: 15.992

Review 3.  Treatment for amphetamine psychosis.

Authors:  Steven J Shoptaw; Uyen Kao; Walter Ling
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

4.  Methamphetamine-induced psychosis: Clinical features, treatment modalities and outcomes.

Authors:  Eileen Thomas; Helena Lategan; Chris Verster; Martin Kidd; Lize Weich
Journal:  S Afr J Psychiatr       Date:  2016-09-29       Impact factor: 1.550

Review 5.  Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?

Authors:  Jørgen G Bramness; Øystein Hoel Gundersen; Joar Guterstam; Eline Borger Rognli; Maija Konstenius; Else-Marie Løberg; Sigrid Medhus; Lars Tanum; Johan Franck
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

Review 6.  Making Sense of: Sensitization in Schizophrenia.

Authors:  Ana Weidenauer; Martin Bauer; Ulrich Sauerzopf; Lucie Bartova; Nicole Praschak-Rieder; Harald H Sitte; Siegfried Kasper; Matthäus Willeit
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-31       Impact factor: 5.176

Review 7.  A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology.

Authors:  Travis A Wearne; Jennifer L Cornish
Journal:  Front Psychiatry       Date:  2018-10-10       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.